WEBULL

Reassessing AptarGroup (ATR) After a 28% Share Price Slide: Is the Market Overlooking Its Growth?

Simply Wall St · 1d ago

AptarGroup (ATR) has quietly slipped about 28% over the past year even as revenue and net income kept growing, a setup that often makes long term investors pause and recheck their valuation assumptions.

See our latest analysis for AptarGroup.

That slide comes after a tougher stretch for the share price, with a 12.05% 3 month share price return and 20.92% year to date share price return both firmly negative, even though the 3 year total shareholder return is still positive at 17.11%. This suggests sentiment has cooled faster than the business fundamentals.

If AptarGroup’s mixed momentum has you rethinking your watchlist, this could be a good moment to explore fast growing stocks with high insider ownership as potential future outperformers.

With earnings still climbing, a sizeable discount to analyst targets, and a modest intrinsic discount, investors now face a key question: is AptarGroup undervalued after its pullback, or is the market already pricing in its future growth?

Most Popular Narrative Narrative: 24.5% Undervalued

With AptarGroup last closing at $121.91 versus a narrative fair value of $161.43, the valuation framework leans firmly toward upside potential.

Ongoing investments in innovation, such as next-generation nasal and derma dispensing systems and expansion into active material sciences, are anticipated to capture share in both pharmaceuticals and high-growth dermacosmetic markets. This strengthens AptarGroup's market leadership and supports long-term top-line growth.

Read the complete narrative.

Want to see what kind of revenue runway and profit profile could justify this upside call, including a premium future multiple for a packaging name? The narrative lays out a detailed earnings path, deliberate margin shifts, and a bold valuation bridge that might surprise you.

Result: Fair Value of $161.43 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, elevated legal costs and uncertain demand for emergency medicine delivery systems could reduce margins and temper this upbeat valuation story.

Find out about the key risks to this AptarGroup narrative.

Build Your Own AptarGroup Narrative

If you would rather dig into the numbers yourself and challenge these assumptions, you can build a custom view in minutes: Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding AptarGroup.

Looking for your next move?

Before you log off, you can scan fresh opportunities on Simply Wall Street’s screener to explore focused ideas that may help reshape your portfolio’s trajectory.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.